advertisement
Abstract #21666 Published in IGR 10-3
Proteomics as a research tool in clinical and experimental ophthalmology
Cryan LM; O'Brien CProteomics - Clinical Applications 2008; 2: 762-775
It is estimated that 37 million people worldwide suffer from blindness and 124 million people have impaired vision. While the relatively recently developed therapies, antivascular endothelial growth factor inhibitors for the treatment of age-related macular degeneration, and prostaglandin analogues for the treatment of glaucoma are beneficial for some patients, there are many individuals with sight-threatening diseases for whom no effective pharmacological therapy is available. For many of these diseases, the molecular mechanisms remain to be comprehensively elucidated, thus precluding the design of successful therapies against specific pathological targets. The current review summarises recent attempts to elucidate molecular mechanisms of ocular diseases, induding diabetic retinal disease, age-related macular degeneration and inherited blindness using proteomic methodologies. A novel hypothesis can be generated from global protein expression analysis of disease tissue, which can then be addressed with cellular and in vivo functional studies. For example, the identification of extracellular carbonic anhydrase from the vitreous of diabetic retinopathy patients using MS based proteomics led to the elucidation of a new pathway involved in intraretinal edema, which could be inhibited by a number of agents targeting different proteins in this pathway in relevant animal models. The potential of protein biomarkers for diagnosis and the identification of novel disease mechanisms are also discussed.
Dr. L.M. Cryan, School of Medicine and Medical Science, UCD Conway Institute, University College Dublin, Dublin 4, Ireland. Lorna.cryan@ucd.ie
Classification:
3.12 Proteomics (Part of: 3 Laboratory methods)
